NLRP3

NLRP3 is a multidomain protein consisting of an N-terminal pyrin domain (PYD), a central NACHT domain with ATPase activity, and a C-terminal leucine-rich repeat (LRR) domain. In resting cells, NLRP3 is kept in an autoinhibited state, often through interactions with chaperones such as SGT1 and HSP90. Upon activation, NLRP3 undergoes a conformational change, oligomerizes, and recruits the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) via PYD–PYD interactions, and pro-caspase-1, forming the inflammasome complex.¹

Activation requires a two-signal model: a priming signal (e.g., Toll-like receptor stimulation) upregulates NLRP3 and pro-IL-1β expression via NF-κB, while a second signal (e.g., ATP, pore-forming toxins, or crystalline substances) triggers assembly. The exact molecular mechanism remains debated, but potassium efflux, mitochondrial reactive oxygen species, and lysosomal damage are key proposed triggers.

Gain-of-function mutations in the NLRP3 gene cause cryopyrin-associated periodic syndromes (CAPS), a spectrum of autoinflammatory diseases including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease. These conditions are characterized by spontaneous inflammasome activation and excessive IL-1β production, leading to fever, rash, and joint pain.²

Beyond monogenic disorders, NLRP3 is implicated in common diseases such as gout, type 2 diabetes, atherosclerosis, and Alzheimer's disease. In gout, monosodium urate crystals activate NLRP3, driving inflammation. In metabolic diseases, elevated glucose and fatty acids can prime and activate the inflammasome, contributing to insulin resistance.³

Given its central role in inflammation, NLRP3 is a promising drug target. Small-molecule inhibitors such as MCC950 (also known as CRID3) block NLRP3 activation and have shown efficacy in preclinical models of CAPS, multiple sclerosis, and myocardial infarction. However, clinical development has been challenging due to species-specific differences and potential off-target effects.⁴

Biologic therapies targeting IL-1β, such as canakinumab and anakinra, are already approved for CAPS and are being tested in other NLRP3-driven conditions. These agents indirectly suppress the downstream effects of NLRP3 activation. Direct NLRP3 inhibitors are still in early-phase trials, with some showing promise in reducing inflammation without compromising host defense.⁵

NLRP3 is not only expressed in immune cells; it also functions in epithelial cells, where it contributes to mucosal defense and tissue repair. For example, intestinal epithelial NLRP3 helps maintain gut barrier integrity and influences the microbiome.⁶

Alternative splicing of the NLRP3 gene produces multiple isoforms, some of which act as dominant-negative regulators, modulating inflammasome activity. Additionally, NLRP3 can be activated by non-canonical pathways, such as through caspase-4/5 in humans, which respond to cytosolic lipopolysaccharide. Post-translational modifications, including ubiquitination and phosphorylation, finely tune its activation, adding layers of regulation that are still being unraveled.

Inflammasome

A multiprotein complex that activates caspase-1 and promotes maturation of pro-inflammatory cytokines.

PYD

Pyrin domain, a protein interaction module involved in inflammasome assembly.

ASC

Apoptosis-associated speck-like protein containing a CARD; an adaptor protein in inflammasomes.

CAPS

Cryopyrin-associated periodic syndromes; a group of autoinflammatory diseases caused by NLRP3 mutations.